Psychopathology in systemic lupus erythematosus. II. Relation to clinical observations, corticosteroid administration, and cerebrospinal fluid C4.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D000342:Affective Symptoms / Q000209:etiology; D001379:Azathioprine / Q000627:therapeutic use; D001927:Brain Diseases / Q000209:etiology; D002493:Central Nervous System Diseases / Q000150:complications; D002986:Clinical Trials as Topic; D003165:Complement System Proteins / Q000134:cerebrospinal fluid*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004569:Electroencephalography; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012559:Schizophrenia / Q000209:etiology
D000305:Adrenal Cortex Hormones; D003520:Cyclophosphamide; D003165:Complement System Proteins; D001379:Azathioprine; D011241:Prednisone